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Abstract
Introduction
Many patients with cancer die in an acute hospital bed, which has been frequently identified
as the least preferred location, with psychological and financial implications. This study
looks at place and cause of death in patients with lung cancer and identifies which factors
are associated with dying in an acute hospital bed versus at home.
Methods and Findings
We used the National Lung Cancer Audit linked to Hospital Episode Statistics and Office for
National Statistics data to determine cause and place of death in those with lung cancer;
both overall and by cancer Network. We used multivariate logistic regression to compare
features of those who died in an acute hospital versus those who died at home.
Results
Of 143627 patients identified 40% (57678) died in an acute hospital, 29% (41957) died at
home and 17% (24108) died in a hospice. Individual factors associated with death in an
acute hospital bed compared to home were male sex, increasing age, poor performance
status, social deprivation and diagnosis via an emergency route. There was marked varia-
tion between cancer Networks in place of death. The proportion of patients dying in an
acute hospital ranged from 28% to 48%, with variation most notable in provision of hospice
care (9% versus 33%). Cause of death in the majority was lung cancer (86%), with other
malignancies, chronic obstructive pulmonary disease (COPD) and ischaemic heart disease
(IHD) comprising 9% collectively.
Conclusions
A substantial proportion of patients with lung cancer die in acute hospital beds and this is
more likely with increasing age, male sex, social deprivation and in those with poor perfor-
mance status. There is marked variation between Networks, suggesting a need to improve
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Introduction
Many patients with cancer die in an acute hospital bed although this may be the location they
prefer the least.[1] Those who die in acute hospital beds have been shown to have a worse qual-
ity of life compared to those who die in hospices or at home.[2] In addition their caregivers are
at increased risk of psychiatric problems after the bereavement.[2,3] There are also cost impli-
cations; research has shown that end of life care in hospital costs three times more than that
delivered in the community.[4,5] The National Health Service (NHS) implemented the
National End of Life Care Programme in 2004 with the aim of allowing more patients to receive
end of life care in their preferred location.
Following this, Gao and colleagues looked at changes in place of death for all cancer deaths
in England between 1993 and 2010.[6] Their work showed that the proportion of patients
dying at home or in hospices in many cancer types has increased but in lung cancer, the biggest
cause of cancer death worldwide, this does not seem to be the case.[6] Many patients with lung
cancer are diagnosed at an advanced stage; in fact 30% of patients are dead within 90 days of
diagnosis, however work suggests that clinicians may leave discussions about end-of-life care
too late to allow patients to achieve their preferred place of death. [7,8]
These data suggest that there is a need to look at the lung cancer population in particular to
try to understand whether there are any features specific to this cancer type which confers an
increased risk of dying in an acute hospital setting. This study aimed to determine place and
cause of death in patients with lung cancer; to identify which features are associated with dying
in an acute hospital bed versus at home; to assess geographical variation in place of death in
England and in addition to identify if time of death following diagnosis impacts on ability to
achieve preferred place of death. A greater understanding of these factors may allow clinicians
to provide better advanced care planning in those at greatest risk.
Methods
Patient population and data source
The National Lung Cancer Audit (NLCA) is a prospective database that collates information
provided by 157 English NHS hospitals on demographic, tumour and treatment for patients
with primary lung cancer. It is linked to data from Hospital Episode Statistics (HES), used to
derive co-morbidity information from coded inpatient episodes, alongside information regard-
ing any interventions and procedures performed, and Office of National Statistics (ONS) that
provides information on date, place and cause of death. Data were provided to the researchers
under the terms of a data sharing agreement from the Health and Social Care Information Cen-
tre (HSCIC). HES and ONS records were linked by staff at the HSCIC to the NLCA using NHS
numbers, with a second check to ensure that dates of birth, post codes and sex match. These
data were then pseudonomised to ensure that the researchers did not have access to any identi-
fiable fields.
We identified all patients diagnosed with non-small cell (NSCLC) or small cell lung cancer
(SCLC) who were recorded in the NLCA between 1st January 2004 and 31st December 2011
inclusive. Those who did not have a date of death recorded on the final date that ONS records
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were updated (March 2013–14 months after the last patient entry into the dataset) were pre-
sumed to still be alive and therefore excluded from further analysis.
Covariate descriptions
Comorbidity was classified according to Charlson score, which was derived to predict the ten-
year mortality for patients with a list of 19 co-morbid conditions. [9]. Clinical coders enter a
primary diagnosis or diagnoses and also a list of co-morbidities for each patient episode in
HES. ICD-10 codes from linked-HES data were used to identify relevant diagnoses which con-
tribute to the Charlson score. Each condition is assigned a score of 1, 2, 3, or 6, depending on
the risk of dying associated with each one and summed to produce a single value for each
patient. As all patients had lung cancer this was not included in the ‘any tumour’ section.
Patients were then categorised into five groups based on their Charlson index score (0, 1, 2, 3
and 4). Townsend Index of deprivation was used as a measure of socioeconomic status. This
is a post-code derived variable which uses 4 markers of social deprivation derived from census
records to categorise patients into quintiles; where 5 is the most deprived and 1 the most afflu-
ent grouping. [10] Pre-treatment records in NLCA were used for stage (grouped as IA/IB, IIA/
IIB, IIIA, IIIB, IV, SCLC limited or SCLC extensive) according to the 7th edition of UICC
TNM, with post-treatment stage used if pre-treatment records were missing. We used pre-
treatment recording of histology and again post-treatment records were used if this was miss-
ing. The NLCA uses the Eastern Cooperative Oncology Group (ECOG) definition of perfor-
mance status (PS). This is a subjective marker which is used to try to quantify general well-
being and ability to carry out activities of daily life and ranges from 0–5, where 0 is fully active,
able to carry on all pre-disease performance without restriction and 4 is completely disabled;
cannot carry on any self-care; totally confined to bed or chair (5 is dead).” [11] We used age at
the time of diagnosis to categorise patients into eight groups (<55, 55–59, 60–64, 65–69, 70–
74, 75–79, 80–84 and85 years). NLCA records were used to identify source of referral. This
refers to the source of referral to the lung cancer team and comprises two emergency routes
(following an emergency admission or following an accident and emergency (A&E) atten-
dance) and seven semi-elective routes which include GP referral and referral from another sec-
ondary care provider or allied health professional.
ONS records were used to characterise place of death as home, acute hospital, residential/
nursing home, hospice, community/rehabilitation hospital or elsewhere. Cause of death was
defined by ONS using the criteria set out in the 10th revision of the “International classification
of diseases” (ICD-10) to determine a single underlying cause of death.[12] England was divided
into 28 cancer networks at the time this data was collected so we used these to assess geographi-
cal variation in place of death. We calculated the proportion of patients dying in each location
and stratified this by cancer network. We also aimed to look at changes in place of death over
the duration of the NLCA. We created four groups based on year of death (2004–2006, 2007–
2008, 2009–2010 and 2011–2013) and looked at the proportion of patients dying in each place,
as described previously, for each year grouping. Work from the Routes From Diagnosis project
showed that 50% of lung cancer patients died within 6 months of diagnosis.[13] To try to iden-
tify if there was a difference in place of death related to time from diagnosis we identified those
who died within 6 months of diagnosis and compared the proportion dying in each location
with those who died more than 6 months after diagnosis.
Statistical methods
All statistical analyses were conducted using Stata MP V.12 (StataCorp, Texas, USA). In order
to compare the factors influencing death in the least preferred location (acute hospital) with
Lung Cancer Place of Death
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home, which is frequently reported to be the desired place of death, we excluded those who
died in other locations from this part of the analysis. Given the median age of diagnosis for
lung cancer is 72 years in the UK we used this as our reference category rather than the youn-
gest age grouping for analysis. Logistic regression was used to calculate odds ratios (OR) for
death within an acute hospital bed within each of the variables described above. We looked at
each variable individually initially, then included those which showed an association in the uni-
variate model (p<0.05) in the multivariate analysis. Likelihood ratio testing (LRT) was used for
all tests of significance. We conducted a sensitivity analysis, excluding those with missing data,
to ensure that our findings were robust. There was minimal change in odds ratios and 95%
confidence intervals, so the results of the original multivariate analysis including all patients
are presented in the results section.
The Healthcare Quality Improvement Partnership (HQIP) approved the use of the National
Lung Cancer Audit for this work. This study does not involve identifiable human participants-
an anonymized dataset was obtained via the HSCIC (under the terms of a data sharing agree-
ment (reference RU943-R1)) who hold data extracted and anonymised specifically for research
use. No study authors had any role in data collection and no personal patient information was
provided in the data which was obtained by the authors. Analysis of these data were reviewed
and approved by the University of Nottingham research ethics committee in December 2012
(reference B15112012LT CHS EPH).
Results
Patient population and data source
Records were identified for 178,178 patients in the NLCA. Of these 24150 were excluded as
they were still alive at the time ONS records were last accessed for dates of death and a further
8702 patients with carcinoid or mesothelioma histological subtypes, 1417 with dates of diagno-
sis after their date of death and 282 with missing information on place of death were also
excluded. This left a final cohort of 143,627 patients.
Demographic features
Overall 58% were male, with a median age at diagnosis of 73 years (interquartile range (IQR)
65–79 years). The majority had NSCLC (88%) and most patients had advanced disease at pre-
sentation; 39% had stage IV NSCLC, 12% stage IIIB, with stages IA to IIA NSCLC comprising
18% collectively. A large proportion of patients were from the most deprived socioeconomic
groups (40% from Townsend quintiles 4 and 5), with a median Charlson co-morbidity score of
1 (IQR 0–3). Median survival from the time of diagnosis was 145 days (IQR 47–346 days).
Place of death
Forty per cent of patients (57678) died in acute hospital beds, 29% (41957) in their own home,
17% (24108) in hospice beds, 8% (12099) died in residential or nursing homes, 4% (5517) in
community or rehabilitation hospitals and 2% (2268) “elsewhere”; which contained those
dying within prisons and mental health institutions. A summary of the demographics of those
dying in each location is provided in Table 1. Those dying in residential or nursing homes were
older than the other localities and had worse WHO performance status at diagnosis (33% PS 3
or 4). Proportionally more of the younger age groups died within hospices. Those from the
most affluent socioeconomic groups (Townsend quintiles 1 and 2) were most likely to die
either in a hospice or at home.
Lung Cancer Place of Death
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Multivariable analysis
In order to compare the odds of death in an acute hospital with home we excluded the 43992
patients who died in the other locations, which left us with a cohort of 99635 patients for the
univariable and multivariable analyses. The results are presented in Table 2. Males were more
likely than females to die in acute hospital beds compared with home (adjusted odds ratio
(OR) 1.14; 95% confidence interval (95% CI) 1.12–1.17). Those in the oldest age bracket (85
years and older) were at increased odds of dying in acute hospital beds (adjusted OR 1.16; 95%
CI 1.08–1.24) compared with all of the younger age groups. There was no real difference
between the other age brackets and likelihood of death within an acute hospital bed. Patients
who presented at WHO performance status 4 (bed bound) were more likely to die in acute hos-
pitals compared with those who were fitter (adjusted OR 1.73; 95% CI 1.61–1.87 for WHO PS
4 compared to WHO PS 0). Again there was only an impact on likelihood of dying with an
acute hospital in the least fit group (WHO PS 4), with no difference between the other classes
in the multivariable analysis. There were increasing odds of death within acute hospitals with
increasing levels of socioeconomic deprivation (adjusted OR 1.31; 95% CI 1.25–1.37) for
Townsend quintile 5 versus quintile 1). Compared with diagnosis via a general practitioner
(GP) referral via all other routes was associated with an increased chance of dying within an
acute hospital bed. This was most marked for the emergency admission route (adjusted OR
1.45; 95% CI 1.39–1.51) and in those diagnosed following attendance at accident and emer-
gency (A&E) departments (adjusted OR 1.43; 95% CI 1.35–1.51). Those with highest stage dis-
ease (stage IV) at diagnosis were less likely to die in acute hospital beds when compared with
those with earlier stage disease at presentation (adjusted OR 0.74; 95% CI 0.70–0.79). In fact
those with stage IA and IB NSCLC were more likely to die in acute hospital beds than all other
stages of NSCLC and also than those with limited and extensive stage SCLC.
Geographical variation in place of death
There was evidence of marked variation in place of death when we stratified patients by each of
the 28 cancer networks (Fig 1). These regional inequalities were most marked in the proportion
of patients dying within hospices, with only 9% in the lowest network dying within this setting
compared with 33% in the highest. There was a 20% difference in the proportion dying in
acute hospital beds between the lowest and highest cancer network (28% to 48%). There was
similar variation in the proportion of patients dying in their own home (22% versus 34% in the
highest and lowest networks respectively).
Changes over time
Changes in place of death between 2004 and 2013 were also assessed (Fig 2), showing a
decrease in the proportion of patients dying in acute hospital beds from 45% in 2004–2006 to
35% in 2011–2013. There has been a corresponding increase in the proportion dying at home
(26% in 2004–2006 compared to 32% in 2011–2013) but only a very small increase (from 16%
to 18%) in the proportion dying within hospice beds. An increase in those dying within resi-
dential and nursing home beds has been mirrored by a reduction in the number of community
hospital beds and corresponding decrease in the proportion dying within that setting.
Time from diagnosis to death
Finally we looked at place of death in those who died in the 6 months following the lung cancer
diagnosis and compared this with those who survived for more than 6 months. These results are
summarised in Table 3. Fifty six per cent of our patients died within the 0–6 month time frame.
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Table 2. Results of univariate andmultivariate analysis comparing death in an acute hospital versus
death at home.
Univariate
analysis
Multivariate
analysis
Death in
acute
hospital
pvalue Death in
acute
hospital
pvalue
OR 95% CI (LRT) OR 95% CI (LRT)
Sex Female 1 p<0.01 1 p<0.01
Male 1.28 1.26–1.31 1.14 1.12–1.17
Age group <55 0.96 0.90–1.03 0.97 0.91–1.04
55–59 0.95 0.89–1.01 0.97 0.91–1.03
60–64 0.97 0.92–1.03 0.98 0.92–1.02
65–69 0.99 0.93–1.05 0.98 0.93–1.04
70–74 1 p<0.01 1 p<0.01
75–79 0.97 0.92–1.03 0.95 0.90–1.01
80–84 1.02 0.96–1.09 0.99 0.93–1.06
85+ 1.23 1.15–1.32 1.16 1.08–1.24
Performance
status
0 1 p<0.01 1 p<0.01
1 1.01 0.97–1.05 0.99 0.95–1.03
2 1.01 0.96–1.06 0.95 0.90–0.99
3 1.09 1.04–1.14 0.97 0.93–1.03
4 2.02 1.88–2.17 1.73 1.61–1.87
Missing 1.2 1.15–1.25 1.08 1.03–1.13
Charlson
score
0 1 p<0.01 1 p = 0.251
1 1.09 1.05–1.13 1.04 1.00–1.08
2 1.08 1.04–1.13 1.02 0.98–1.06
3 1.16 1.10–1.22 1.06 1.01–1.12
4 1.07 1.03–1.10 0.99 0.96–1.03
Townsend
quintile
1 1 p<0.01 1 p<0.01
2 1 0.96–1.05 1.01 0.96–1.06
3 1.13 1.08–1.18 1.13 1.08–1.18
4 1.19 1.14–1.25 1.19 1.13–1.24
5 1.32 1.26–1.38 1.31 1.25–1.37
Missing 1.42 1.35–1.49 1.38 1.31–1.46
Histology Adenocarcinoma 1 p<0.01 1 p = 0.026
Squamous cell 0.95 0.91–0.99 0.92 0.88–0.97
NSCLC NOS 0.96 0.92–1.00 0.97 0.93–1.01
SCLC 0.95 0.90–0.99 0.92 0.88–0.98
Other 0.94 0.88–1.01 0.92 0.86–0.99
Missing 1.11 1.07–1.15 0.97 0.94–1.01
Stage IA/ IB 1 p<0.01 1 p<0.01
IIA/ IIB 0.85 0.78–0.92 0.86 0.79–0.94
IIIA 0.74 0.69–0.79 0.76 0.71–0.82
IIIB 0.78 0.73–0.83 0.79 0.74–0.84
IV 0.77 0.73–0.81 0.74 0.70–0.79
SCLC Limited 0.71 0.62–0.82 0.76 0.66–0.87
SCLC Extensive 0.85 0.78–0.94 0.86 0.77–0.95
Missing 0.9 0.85–0.95 0.84 0.79–0.89
(Continued)
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Proportionally more of these patients died in acute hospital beds (44% compared to 35% of
those who lived for over 6 months). Patients who survived for over 6 months after their diagno-
sis were more likely to die at home (32% versus 27%) or in a hospice setting (19% versus 15%)
than those who died in the first 6 month window. Those who died within the initial 6 months
after diagnosis were older (median age at diagnosis of 74 years (IQR 66–80) compared with
median age at diagnosis of 71 years (IQR 63–78) in the group who lived for longer than 6
months). There were similar proportions of males and females between the 2 groups (58%
males in the group who died within 6 months of diagnosis versus 56% in the group who sur-
vived for longer). There was a marked difference in the distribution of performance status when
comparing the 2 groups; 50% of those in the group who survived more than 6 months were
deemed to beWHO PS 0 or 1 at diagnosis compared with only 23% of those in the group who
died within 0–6 month time frame. There were proportionally more patients who were felt to be
WHO PS 3 or 4 in the cohort who died within 6 months (30% versus 8%). Seventeen per cent of
those in the group who lived for longer than 6 months presented with lung cancer that was stage
IA-IIB compared with only 5% in the group who died within 6 months, whilst 48% of the group
who died within 6 months had stage IV disease at presentation versus 27% in the group who
survived for longer. The group who died within 6 months were also proportionally more likely
to be diagnosed via an emergency admission route (28% versus 12%), with only 40% referred
from their GP compared with 55% in the group who lived for longer than 6 months.
Cause of death
Cause of death was recorded as lung cancer in 86% (123147) of patients. Death was attributed
to other malignancies in 6% (8996) of cases, chronic obstructive pulmonary disease (COPD) in
1.4% (2021) and ischaemic heart disease (IHD) in 1.5% (2172), with a variety of other condi-
tions comprising the remaining 5%.
Discussion
Our results show that, although there has been a 10% reduction in the proportion of patients
with lung cancer dying in acute hospital beds between 2004 and 2013, 35% still die within that
setting. Old age ( 85 years), male sex, socioeconomic deprivation, WHO performance status
Table 2. (Continued)
Univariate
analysis
Multivariate
analysis
Death in
acute
hospital
pvalue Death in
acute
hospital
pvalue
OR 95% CI (LRT) OR 95% CI (LRT)
Source of
referral
Emergency
admission
1.52 1.46–1.58 1.45 1.39–1.51
GP referral 1 p<0.01 1 p<0.01
Consultant
referral
1.16 1.13–1.20 1.13 1.09–1.17
A&E 1.49 1.41–1.57 1.43 1.35–1.51
Other 1.21 1.15–1.27 1.16 1.10–1.23
Unknown 1.21 1.14–1.28 1.16 1.09–1.23
LRT- likelihood ratio test
doi:10.1371/journal.pone.0161399.t002
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4 at diagnosis and emergency route to diagnosis are all strongly and independently associated
with increased likelihood of death within acute hospitals, although death in this location is less
likely with more advanced stage disease at presentation. In additional there is evidence of geo-
graphical variation in place of death, particularly with regard to provision of hospice services.
Fig 1. Place of death stratified by cancer Network.
doi:10.1371/journal.pone.0161399.g001
Fig 2. Changes in place of death between 2004 and 2013.
doi:10.1371/journal.pone.0161399.g002
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Given the often advanced stage of disease at presentation and poor prognosis it is unsurprising
that the majority of patients with a diagnosis of lung cancer are recorded as having died of the
underlying disease.
Strengths and limitations
This is one of the first studies to look in detail at both place and cause of death in lung cancer
patients specifically and the large number of patients and representative nature of the popula-
tion is a particular strength. The NLCA has previously been validated as a reliable source of the
UK lung cancer data and currently has in excess of 90% case ascertainment. [14] Although
data completeness is improving in the NLCA, missing data are still a challenge. A sensitivity
Table 3. Demographic features of patients comparing those who died within 0–6months following
diagnosis and > 6months.
Death within 0–6 months
of diagnosis
Death > 6 months after
diagnosis
N = 80229 % N = 63398 %
Place of death Home 21574 27 20383 32
Acute hospital 35504 44 22174 35
Residential/ nursing
home
6398 8 5701 9
Hospice 12105 15 12003 19
Community/ rehab
hospital
3281 4 2236 4
Elsewhere 1367 2 901 1
Sex Female 33333 42 27607 44
Male 46896 58 35791 56
Median age at
diagnosis
Years (IQR) 74 (66–80) 71 (63–78)
Performance
status
0 5110 6 12163 19
1 13858 17 19707 31
2 15054 19 9418 15
3 17578 22 4728 7
4 6731 8 658 1
Missing 21898 27 16724 26
Stage IA/ IB 2061 3 6807 11
IIA/ IIB 1713 2 3803 6
IIIA 4030 5 6860 11
IIIB 8439 11 9114 14
IV 38540 48 17136 27
SCLC Limited 378 0.5 968 2
SCLC Extensive 2148 3 1395 2
Missing 22920 29 17315 27
Source of referral Emergency
admission
15269 19 5049 8
GP referral 31763 40 35030 55
Consultant referral 15760 20 12217 19
A&E 7476 9 2670 4
Other 5260 7 4643 7
Unknown 4701 6 3789 6
doi:10.1371/journal.pone.0161399.t003
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analysis conducted excluding those with missing data fields did not change any of the results
substantially suggesting that the missing data did not affect the validity of our findings. The
population in NLCA is predominantly white which does make extrapolation of these results to
other ethnic groupings difficult. In addition work by Gao et al [6] has suggested that marital
status may be relevant to place of death; with those who are single, widowed or divorced being
more likely to die in the hospital setting. These data are not routinely recorded in our datasets
so there may be confounding due to inability to adjust for this. We were also unable to take
into account patient preference in place of death or assess whether this might change when
faced with worsening symptoms in the terminal phase of the illness. However, although we
accept that not all patients will choose to die at home existing evidence suggests that this is the
preference for most. [1]
Other work in the literature
Gao and colleagues used ONS data to look at changes in place of death for all cancer deaths in
England between 1993 and 2010.[6] They also looked at some features associated with death at
home or in a hospice. Although there was a decrease in the overall proportion of cancer
patients dying in hospital over this time frame there was little change in the lung cancer group.
Similar to our study they found that male sex, increasing age, social deprivation and in addition
marital status were independently associated with increased likelihood of dying in acute hospi-
tals. A further piece of work by Gomes et al [15] looked at changes in place of death between
2004 and 2010 for both cancer and non-cancer patients and showed that there has been a small
rise in the proportion of patients overall dying at home over this time period; with 27% of all
cancer patients dying in their own home in 2010. This is very similar to the 29% we observed
in the lung cancer population for the years 2009–2010. In addition Davies et al [16] assessed
changes in place of death for cancer patients in the Thames Cancer Registry over a 17 year
period (1985–2002), showing a decrease in the proportion of patients dying within acute hospi-
tal beds from 67% to 47% by 2002. They also showed that those who were older (> 75 years)
were more likely to die in acute hospital beds. A randomised controlled trial conducted by
Brumley et al [17] assigned patients with a terminal prognosis to usual care or in-home pallia-
tive care, which comprised not only pain and symptom relief, but a variety of educational, med-
ical and social support services. They looked at visits to the emergency department (ED) and
also place of death in both groups and showed that the group receiving palliative care support
had fewer visits to the ED and also were 20% more likely to die at home compared to the usual
care arm. This highlights the key role that early and effective palliative care has to play in
ensuring that wherever possible patients are able to achieve their preferred place of death. Stud-
ies consistently show that patients with lung cancer are more likely to die in acute hospital beds
than patients with many other solid organ tumours and there is a suggestion that this is due to
late discussions about end-of-life care [7] in combination with a rapidly progressive disease. A
study looking at hospitalisations towards the end of life specifically in poor-prognosis cancer
types in the United States showed that high-intensity inpatient care (including administration
of chemotherapy and admission to Intensive care units) was delivered close to death in many
patients, which may prevent better supportive care being delivered and end-of-life decisions
being made in a timely manner.[18] There is evidence that patients who discuss end of life care
preferences are more likely to die within home or hospice settings however we did not have the
data available to know what extent these factors contributed to death within acute hospital set-
tings in our cohort.[19,20] It may be that those patients who survived for more than 6 months
after diagnosis had more time to plan and discuss preferences for end of life care than those
who died earlier in the disease process possibly explaining in part the smaller proportion of
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patients in this group who died in acute hospital beds when compared with those who died in
the 6 months immediately following their diagnosis. A variety of patient and tumour features
also contribute to mortality within the initial 6 months following diagnosis which may make
discharge from acute hospital beds more difficult to facilitate. Work from the National Cancer
Intelligence Network (NCIN) “Routes to Diagnosis” project has shown that lung cancer
patients who present via the emergency route have a much lower 1 year survival [21] which
explains why proportionally more patients in the group who died within 0–6 months were
diagnosed via an emergency admission route. In addition performance status has been previ-
ously shown to be an independent predictor for overall survival in lung cancer, with the differ-
ences in performance status marked between those who died within 6 months and those who
lived for longer in our cohort.[22]
Work performed in South East England has suggested that those from ethnic minority
groups were more likely to die in hospital beds and less likely to access hospice services than
white patients, which suggests there may be an additional need to look in more detail at the
ethnicity of patients and the part it has to play in place of death.[23] The wide geographic varia-
tions in place of death are likely to represent service availability and accessibility. A study by
Gatrell et al [24] looked at variations in geographic access to hospices in England and Wales
and showed that there are inequities in provision of beds between regions, with the lowest
numbers of beds per 1000 cancer deaths in the North East and East Midlands; which corre-
sponds to the two cancer Networks with the lowest proportion of patients dying within hospice
beds in our study (North of England and East Midlands). Furthermore a piece of work from
Sleeman et al [25] suggested that those from a more affluent background were more likely to
die in a hospice setting than those from the most deprived socio-economic grouping, suggest-
ing that inequities in access are not only geographic.
Interpretation of the results
The fact that those with higher stage disease at presentation are less likely to die within an
acute hospital setting was an unexpected finding, however it may indicate that we are better
at offering early palliative care to patients with non-curative disease to try to ensure that they
achieve their preference in place of death compared with those who undergo surgery or
aggressive systemic anti-cancer treatment; where the focus is on management with curative
intent rather than end of life care. Those with higher stage disease would also therefore be
less likely to suffer morbidity and mortality related to treatment side effects which may neces-
sitate hospitalisation in the latter days of life. It may also be the case that recognition that the
patient has reached the terminal phase of the disease, with a shift in the treatment paradigm
from curative to palliative, may occur too late to allow the preference in place of death to be
met. There is no study which has specifically addressed this question however. It is difficult
to suggest what the optimal proportion of patients dying in acute hospital settings should be
as many patients develop distressing symptoms in the latter days of life which necessitate
hospitalisation. Only 28% of patients in the lowest cancer network died in acute hospital beds
(due principally to a large number of in-hospice deaths in this region) so it is not unreason-
able to suggest that this could be the gold standard given optimal service provision and
resource allocation, although we recognise that there are differing social and patient demo-
graphic features which also may influence this between regions. Another option may be to
optimise palliative services for these patients on site at acute hospitals or provide a more inte-
grated community and acute hospital service than many regions currently have to facilitate
discharge to a more appropriate setting.
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Clinical relevance and conclusions
A substantial proportion of patients with lung cancer die in acute hospital beds and this is
more likely in the most elderly (85 years), males, those who are socially deprived, those diag-
nosed via an emergency admission route and in those with the worst performance status
(WHO PS 4). There is marked geographical variation, suggesting a need to improve end-of-life
planning in those at greatest risk, and to review the allocation of resources to provide more
hospice beds, enhanced community support and ensure equal access. Increasing the proportion
of patients dying in the community would undoubtedly offer cost savings in addition to psy-
chological benefits.
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